Jan Albert Kuivenhoven Intracellular actions of PCSK9
Anthony Wierzbicki Back to basics on cost-effectiveness
Henry Ginsberg Where are we with CVD prevention guidelines?
Chris Packard Preventing cardiovascular disease: the value of early signs of cardiac injury
Brian Ference What can we learn from Mendelian randomisation about the impact of lipid lowering on CVD and risk of dysglycaemia?
Rodrigo Alonso Insights from Chile: Rodrigo Alonso, Clínica Las Condes, Santiago de Chile
Raul Santos Insights from Brazil: Raul Santos, InCor-University of Sao Paulo
Francois Mach Outcomes data are critical
Gunnar Karlsson Collaboration between patient associations and healthcare professionals is key
David Hare Many key barriers are amenable to change; new strategies are needed
What prevents high risk patients gaining access to treatment with PCSK9 inhibitors?
Anthony Wierzbicki PCSK9 inhibitors: Who and when to treat?
Steve Nicholls Current status of IVUS studies of plaque burden: what next with GLAGOV?
John Chapman PCSK9 inhibition at the limits
Bo Angelin How does PCSK9 inhibition influence cholesterol metabolism in humans?
PCSK9 Inhibitors for Treatment of High Cholesterol levels: Effectiveness and Value
Sergio Fazio Lipoprotein-associated PCSK9: Physiological implications?
Chris Packard Legacy effects: Does early intensive LDL lowering treatment modify the atherosclerotic process?
Jan Boren ApoB-containing lipoproteins and the pathophysiology of atherosclerotic vascular disease: update
Steve Nicholls Innovative PCSK9-targeted therapeutics: siRNA